BioStock: PHI’s CEO comments on the approved US listing
![](https://phiab.com/wp-content/uploads/2024/08/Biostock-PHI-CEO-comments-on-the-approved-US-listing.jpg)
Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading
![Biostock-regenerative-medicine-phi](https://phiab.com/wp-content/uploads/2022/10/Biostock-regenerative-medicine-phi-320x180.jpg)
BioStock: PHI expands market potential with regenerative medicine opportunity
BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
![fill or kill podcast](https://phiab.com/wp-content/uploads/2022/04/fillorkill_podcast-320x180.jpg)
PHI som gäst i Fill or Kill podcast: Avsnitt 366
Lyssna på Fill or Kill intervjun med PHI vd Peter Egelberg.
![Generic Business Image](https://phiab.com/wp-content/uploads/2022/03/business-2-320x180.jpg)
BioStock: PHIs CEO eyes new business opportunities
BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.
![Two images showing cell culturing of today and tomorrow](https://phiab.com/wp-content/uploads/2021/12/Cell-culturing-today-and-tomorrow-320x180.jpg)
Aktiespararna: PHIs teknik är nu redo att förvandla regenerativ medicin till framtidens sjukvård
PHI går i spetsen för nästa generation av cell-analys instrumentering, och gör nu en företrädesemission för att kunna fortsätta expandera inom klinisk tillämpning. Läs hela intervjun på Aktiespararna.